neomycin/polymyxin B/ bacitracin/pramoxine (OTC)

Frequency Not Defined

Allergic contact dermatitis

Contraindications

Hypersensitivity

Cautions

Ototoxicity and nephrotoxicity possible if treating large surface area or chronic use

Pregnancy category: C

Lactation: unknown if neomycin, polymyxin B, or bacitracin excreted in breast milk; systemic absorption of topical lidocaine has been reported

Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Neomycin, polymyxin B, and bacitracin elicit bacteriostatic activity

Pramoxine provides local anesthetic effect